See updated messages from the NIDA HRP scientific leadership team.
Funding Opportunities of Note
- NIDA Avant-Garde Award Program for HIV and Substance Use Disorder Research (DP1, Clinical Trial Optional) PAR-23-269
- Avenir Award Program for Research on Substance Use Disorders and HIV (DP2 Clinical Trial Optional) PAR-23-125
- High Priority HIV and Substance Use Research (R01 Clinical Trial Optional) RFA-DA-22-040
- Notice of Change to Application Due Date for RFA-DA-22-040, "High Priority HIV and Substance Use Research (R01 Clinical Trial Optional)" NOT-DA-23-041
- High Priority HIV and Substance Use Research (RM1 Clinical Trial Optional) RFA-DA-25-060
- AIDS-Science Track Award for Research Transition (R03 Clinical Trial Optional) PAS-21-270
- Notice of Special Interest (NOSI): Research to Address Ending the HIV Epidemic Initiative Goals Relevant to Substance Using Populations At-Risk for or Living with HIV, NOT-DA-23-013
Basic Research
- Research on the Neuro-Immune Axis in the context of HIV and Substance Use (R01 Clinical Trial Not Allowed) RFA-DA-25-004
- Research on the Neuro-Immune Axis in the Context of HIV and Substance Use (R21 Clinical Trial Not Allowed) RFA-DA-25-005
- Chemical Probes and Drugs for Modulating HIV Transcription in the Context of Substance Use Disorders (R21 Clinical Trial Not Allowed) RFA-DA-25-008
- Chemical Probes and Drugs for Modulating HIV Transcription in the Context of Substance Use Disorders (R01 Clinical Trial Not Allowed) RFA-DA-25-007
- Interplay of Autophagy Regulated Cell Death and HIV Pathogenesis in Substance Use Disorders (R01 Clinical Trial Not Allowed) RFA-DA-25-009
- Interplay of Autophagy Regulated Cell Death and HIV Pathogenesis in Substance Use Disorders (R21 Clinical Trial Not Allowed) RFA-DA-25-010
- Mechanistic Studies of the Effects of Psychosocial Stress on Complex Morbidity Involving SUD, Psychiatric Disorders, and HIV (R01 Basic Experimental Studies with Humans (BESH) Required) RFA-DA-24-006
- Mechanistic Studies of the Effects of Psychosocial Stress on Complex Morbidity Involving SUD, Psychiatric Disorders, and HIV (R01 Clinical Trials Optional) RFA-DA-24-005
- Effect of HIV and Substance Use Comorbidity on the Placenta and Maternal Outcomes (R01 Clinical Trial Optional) RFA-DA-25-021
- Targeting Inflammasomes in HIV and Substance Use (R01 Clinical Trial Not Allowed) RFA-DA-25-012
- Targeting Inflammasomes in HIV and Substance Use (R21 Clinical Trial Not Allowed) RFA-DA-25-013
- Advancing Technologies to Improve Delivery of Pharmacological, Gene Editing, and other Cargoes for HIV and SUD Mechanistic or Therapeutic Research (R01 Clinical Trial Optional) RFA-DA-25-022
- Applying Imaging Pipelines for Spatial Characterization of Cellular Interactions in HIV-related CNS Pathology and/or Substance Use (R61/R33 Clinical Trial Not Allowed) RFA-DA-24-030
- Exploratory studies to investigate mechanisms of HIV infection, replication, latency, and/or pathogenesis in the context of substance use disorders (R01 Clinical Trial Not Allowed) RFA-DA-25-011
- Single Cell Opioid Responses in the Context of HIV (SCORCH) Program: Data Mining and Functional Validation (R21 Clinical Trial Not Allowed) RFA-DA-25-017
- Single Cell Opioid Responses in the Context of HIV (SCORCH) Program: Data Mining and Functional Validation (R01 Clinical Trial Not Allowed) RFA-DA-25-016
- Single Source: Single Cell Opioid Responses in the Context of HIV (SCORCH) Program: Data Coordination, Analysis, and Scientific Outreach (UM1 Clinical Trial Not Allowed) RFA-DA-25-015
- Microglial Pathophysiology in Comorbid Substance Use Disorder (SUD) and HIV (R61/R33 Clinical Trial Not Allowed) RFA-DA-25-014
- NIDA REI: Research on Neurocognitive Mechanisms Underlying the Impact of Structural Racism on the Substance Use Trajectory (R61/R33 Clinical Trial Optional) RFA-DA-23-028
- NIDA REI: Research at Minority Serving Institutions on Neurocognitive Mechanisms Underlying the Impact of Structural Racism on the Substance Use Trajectory (R61/R33 Clinical Trial Optional) RFA-DA-23-029
- Notice of Special Interest (NOSI): Advancing HIV/AIDS Research through Computational Neuroscience. NOT-DA-21-030
- Ex Vivo Models for Studies at the Intersection of HIV and Poly-Substance Use (R01 Clinical Trial Not Allowed) RFA-DA-24-001
Clinical, Epidemiological, and Implementation Science Research
- Notice of Special Interest (NOSI): Saving Lives: Integrating Overdose Education and Naloxone Distribution (OEND) into HIV Prevention and Care Settings for People Who Use Addictive Substances NOT-DA-25-031
- Ending the Epidemic: New Models of Integrated HIV/AIDS, Addiction, and Primary Care Services (R01 Clinical Trial required) RFA-DA-25-019
- Ending the Epidemic: New Models of Integrated HIV/AIDS, Addiction, and Primary Care Services (R34 Clinical Trial Optional) RFA-DA-25-059
- Cohort Studies of HIV/AIDS and Substance Use (U01 Clinical Trial Not Allowed) RFA-DA-25-003
- Engaging Survivors of Sexual Violence and Trafficking in HIV and Substance Use Disorder Services (R34 Clinical Trial Optional) RFA-DA-25-018
- Ending the Epidemic: New Models of Integrated HIV/AIDS, Addiction, and Primary Care Services (R34 Clinical Trial Optional) RFA-DA-25-059
- Addressing HIV in highest risk sexual and gender minorities (R34 Clinical Trial Required) RFA-DA-25-002
- Addressing HIV in Highest Risk Sexual and Gender Minorities (R01 Clinical Trial Optional) RFA-DA-25-001
- Development & Testing of Novel Interventions to improve HIV Prevention, Treatment, and Program Implementation for People Who Use Drugs (R34 Clinical Trial Required) PA-21-205
- NIDA REI: Reaching Equity at the Intersection of HIV and Substance Use: Novel Approaches to Address HIV Related Health Disparities in Underserved Racial/Ethnic Populations (R01 Clinical Trial Optional) RFA-DA-23-023
- NIDA REI: Reaching Equity at the Intersection of HIV and Substance Use: Novel Approaches to Address HIV Related Health Disparities in Underserved Racial/Ethnic Populations (R34 Clinical Trial Optional) RFA-DA-23-024
- Stimulants and HIV: Addressing Contemporary and Recurring Epidemics (R61/R33 - Clinical Trial Required). RFA-DA-23-008
- Behavioral and Integrative Treatment Development Program (R01 Clinical Trial Optional). PAR-22-182
- Behavioral and Integrative Treatment Development Program (R34 Clinical Trial Optional). PAR-22-183
- Notice of NIDA Participation in NOT-MH-21-105, "Notice of Special Interest: Advancing Health Communication Research on HIV Prevention, Treatment and Cure"
- Pilot Health Services and Economic Research on the Treatment of Drug, Alcohol, and Tobacco Use Disorders (R34 - Clinical Trial Optional) PA-21-180
- Notice of Special Interest (NOSI): Telehealth Strategies for Individuals with HIV and Substance Use Disorders. NOT-DA-21-019
- Mechanism for Time-Sensitive Drug Abuse Research (R21 Clinical Trial Optional) PAR-22-027
- Accelerating the Pace of Drug Abuse Research Using Existing Data (R21 Clinical Trial Optional) RFA-DA-24-037
- Notice of Special Interest (NOSI): Using Data to Advance HIV Epidemic Knowledge and Program Planning. NOT-DA-21-007
Medical Consequences and Cross-Cutting Research
- Notice of Special Interest (NOSI): Pharmacogenomic Approaches to Enhancing HIV and Substance Use Disorder (SUD) Treatment Strategies, A jump into Precision Medicine – NOT-DA-24-001
- Notice of Special Interest (NOSI): Chemsex and HIV: prevalence, medical/psychosocial consequences, and treatment, NOT-DA-24-002
- Notice of Special Interest (NOSI): Long-Term Neurocognitive Consequences of COVID-19 in Individuals Living with HIV and Substance Use Disorders. NOT-DA-21-018
- Notice of Special Interest (NOSI): Medical Consequences of Smoking and Vaping Drugs of Abuse in Individuals with HIV and COVID-19. NOT-DA-21-017
Program Projects and Center Grants
- NIDA Program Project Grant Applications (P01 Clinical Trial Optional). PAR-23-064
- NIDA Research Center of Excellence Grant Program (P50 Clinical Trial Optional) PAR-23-076
- NIDA Core "Center of Excellence" Grant Program (P30 Clinical Trial Optional) PAR-23-049
Career Development and NRSA Fellowship Grants
- NIDA Mentored Clinical Scientist Development Program Award in Substance Use and Substance Use Disorder Research (K12 Clinical Trial Optional) PAR-24-089
- NIDA Training and Career Development Fellowships & Grants